Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Executive Summary
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
You may also be interested in...
Nabriva Hopes To Relaunch Xenleta In Community Setting As Pandemic Subsides
Moving away from its earlier hospital-based focus with the novel antibiotic, Nabriva also thinks selling Merck & Co.’s Sivextro will provide complementary business.
Antibiotic Action Fund Remains Stop-Gap As Industry Waits For Reimbursement Legislation
Pharma-backed investment fund to combat antimicrobial resistance aims to find Phase II-ready programs, but can’t generate a constant flow of innovation without better ‘pull’ incentives, industry says.
AMR Action Fund Will Start Screening Antibiotic Candidates Early Next Year
The industry-backed investment fund to combat antimicrobial resistance hopes to be operational by end of year and begin assessing programs to invest in during the first quarter of 2021.